Definium Therapeutics, Inc. (DFTX)
| Market Cap | 2.29B +307.0% |
| Revenue (ttm) | n/a |
| Net Income | -237.54M |
| EPS | -2.49 |
| Shares Out | 109.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,435,669 |
| Open | 21.05 |
| Previous Close | 21.35 |
| Day's Range | 20.80 - 21.42 |
| 52-Week Range | 6.28 - 26.25 |
| Beta | 2.38 |
| Analysts | Strong Buy |
| Price Target | 38.38 (+82.85%) |
| Earnings Date | May 7, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $38.38, which is an increase of 82.85% from the latest price.
News
Definium Therapeutics says first patient dosed in Ascend study
Definium Therapeutics (DFTX) announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluating DT120 ODT for the treatment of major depressive disorder. The Ascend…
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
Definium Therapeutics price target lowered to $48 from $49 at Piper Sandler
Piper Sandler analyst David Amsellem lowered the firm’s price target on Definium Therapeutics (DFTX) to $48 from $49 and keeps an Overweight rating on the shares following quarterly results. Taking…
Definium Therapeutics reports Q1 EPS (71c), consensus (49c)
As of March 31, 2026, Definium Therapeutics (DFTX) had cash, cash equivalents and investments of $373.4 million compared to $411.6 million as of December 31, 2025. Based on the Company’s…
Definium Therapeutics Earnings Call Transcript: Q1 2026
Late-stage clinical programs for DT120 ODT in MDD and GAD are progressing, with three pivotal phase III readouts expected in 2026. Q1 2026 saw increased R&D and G&A expenses, a net loss of $77.1 million, and a strong cash position of $373.4 million, supporting operations into 2028.
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...
Psychedelic: Exclusive talk with biopharma company Definium
In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Rob Barrow, Chief Executive Officer, and Daniel Karlin, Chief Medical Officer, at Definium Therapeutics (DFTX), a late-s...
Definium Therapeutics price target raised to $40 from $25 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $40 from $25 and keeps an Outperform rating on the shares. The firm attended Definium’s Investor and Analyst Day,…
Definium Therapeutics highlights advancement of DT120 ODT
Definium Therapeutics (DFTX) “highlighted the advancement of its DT120 ODT (lysergide tartrate) clinical program and commercial strategy in major depressive disorder and generalized anxiety disorder, ...
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics Transcript: Investor Day 2026
DT120 is advancing through multiple phase III trials for GAD, MDD, and PTSD, with three pivotal data readouts expected in 2024. The commercial strategy targets high-need patients and leverages robust IP, payer support, and operational learnings from esketamine. Strong clinical results and broad stakeholder engagement position DT120 for significant market impact.
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
How an Executive Order Boosted Definium Therapeutics Stock (DFTX) Today
Definium Therapeutics stock climbed on Monday after the White House announced a new Executive Order focused on psychedelic drugs.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying ...
Definium Therapeutics initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $30 price target The firm is citing its view for DTX120 having a high probability-of-success…
Definium Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Pivotal phase III data for DT120 in MDD and GAD are expected this year, with studies designed for robust efficacy and durability assessment. GAD prevalence is rising, and current treatments are inadequate, positioning the drug for strong market impact if results are positive.
Definium Therapeutics price target raised to $38 from $25 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Definium Therapeutics (DFTX) to $38 from $25 and keeps a Buy rating on the shares. The firm believes the shares…
Definium Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Definium Therapeutics (DFTX) with an Overweight rating and $49 price target The firm says Definium’s orally disintegrating tablet form of lysergide D-tartrate, DT12...
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...